These brands will be transferred from Novartis Pharma K K to Sun Pharma's subsidiary in Japan beginning October 2016.
Sun Pharma has also signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands that include drugs for Parkinson's disease, epilepsy, depression and hyper-tension.
Under this alliance, following the transfer of manufacturing & marketing rights to Sun Pharma's subsidiary in Japan, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals.